Ovarian reserve in Fragile X premutation carriers
Part of Genetic & congenital, Women’s health & pregnancy clinical trials.
This study looks at egg supply (ovarian reserve) in women who carry the Fragile X premutation. It aims to understand fertility potential better and help guide future family planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between the ages of 18 and 40.
- You carry the Fragile X premutation (any number of CGG repeats is okay).
- You have not had any ovarian surgery, radiotherapy, chemotherapy, or endometriosis that could affect your ovaries.
- You are enrolled in a social security plan (or equivalent) and are not under legal guardianship or protection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how common endometriosis and adenomyosis are in women who preserve their fertility for non-medical reasons. It may help understand these conditions better.
This research study looks at genetic differences in women who have experienced early menopause or severe irregular periods before age 40, with no known cause. By comparing your genes to women with normal menstrual cycles, researchers hope to understand what causes this condition and potentially develop better treatments.
This study compares egg supply (“ovarian reserve”) in women with multiple sclerosis to women without MS. It may help doctors understand how MS affects reproductive health and egg supply.
This study looks at fertility in women who carry a BRCA1 or BRCA2 gene mutation. It aims to understand how these mutations might affect a woman's ability to have children by comparing them to family members without the mutation.
This study looks at DNA changes to understand the cause of premature ovarian insufficiency (early menopause). It may help clarify what’s happening in your body and guide future care.
This trial tests an investigational medicine called MRM-3379 in males with Fragile X syndrome. It looks at how the medicine affects thinking and behavior over time.
Hear when a new FMR1 Gene Premutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.